Helen Dignum

Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial

Mark T. Drayson, Stella Bowcock, Tim Planche et al. · The Lancet Oncology · 2019 · 160 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

Alan K. Burnett, Robert K. Hills, Ann E. Hunter et al. · Leukemia · 2012 · 159 citations · Full text

Medicine, Hematology, Pharmacology +9

Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia

Mike Dennis, Nigel H. Russell, Robert K. Hills et al. · Blood · 2015 · 49 citations · Full text

Medicine, Hematology, Oncology +16

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> Mutations

Nigel H. Russell, Charlotte S. Wilhelm-Benartzi, Jad Othman et al. · Journal of Clinical Oncology · 2024 · 41 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Quantification improves the prognostic value of CD38 expression in B‐cell chronic lymphocytic leukaemia

Tryfonia Mainou‐Fowler, Helen Dignum, Penelope R. A. Taylor et al. · British Journal of Haematology · 2002 · 33 citations

Medicine, Hematology, Oncology +16